NeoGenomics Historical Financial Ratios
| NEO Stock | USD 17.56 0.34 1.90% |
NeoGenomics is lately reporting on over 113 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 70.22 will help investors to properly organize and evaluate NeoGenomics financial condition quickly.
NeoGenomics |
About NeoGenomics Financial Ratios Analysis
NeoGenomicsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate NeoGenomics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on NeoGenomics financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across NeoGenomics history.
NeoGenomics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing NeoGenomics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on NeoGenomics sales, a figure that is much harder to manipulate than other NeoGenomics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is NeoGenomics dividend as a percentage of NeoGenomics stock price. NeoGenomics dividend yield is a measure of NeoGenomics stock productivity, which can be interpreted as interest rate earned on an NeoGenomics investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Most ratios from NeoGenomics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into NeoGenomics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.At this time, NeoGenomics' Sales General And Administrative To Revenue is very stable compared to the past year. As of the 13th of December 2024, Average Inventory is likely to grow to about 516.6 K, while Price To Sales Ratio is likely to drop 3.26.
| 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 85.72 | 80.96 | 70.22 | PTB Ratio | 1.15 | 2.16 | 2.05 |
NeoGenomics fundamentals Correlations
Click cells to compare fundamentals
NeoGenomics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
NeoGenomics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 7.19 | 13.15 | 8.45 | 2.25 | 3.43 | 3.26 | |
| Ptb Ratio | 3.6 | 5.79 | 8.42 | 1.15 | 2.16 | 2.05 | |
| Days Sales Outstanding | 84.14 | 87.74 | 84.5 | 85.72 | 80.96 | 70.22 | |
| Book Value Per Share | 5.05 | 6.39 | 9.24 | 8.03 | 7.5 | 7.88 | |
| Free Cash Flow Yield | 0.001137 | (0.004727) | (0.0222) | (0.0844) | (0.0151) | (0.0159) | |
| Stock Based Compensation To Revenue | 0.0245 | 0.023 | 0.0464 | 0.0484 | 0.0416 | 0.0437 | |
| Pb Ratio | 3.6 | 5.79 | 8.42 | 1.15 | 2.16 | 2.05 | |
| Ev To Sales | 7.09 | 13.13 | 9.06 | 2.93 | 3.89 | 3.69 | |
| Free Cash Flow Per Share | 0.0332 | (0.25) | (0.76) | (0.78) | (0.24) | (0.23) | |
| Roic | 0.0304 | 7.31E-4 | (0.003372) | (0.0904) | (0.0657) | (0.069) | |
| Inventory Turnover | 14.72 | 8.76 | 12.71 | 13.26 | 14.37 | 21.05 | |
| Net Income Per Share | 0.0797 | 0.0384 | (0.0696) | (1.16) | (0.7) | (0.67) | |
| Days Of Inventory On Hand | 24.8 | 41.68 | 28.73 | 27.53 | 25.41 | 17.59 | |
| Payables Turnover | 10.83 | 10.36 | 16.59 | 15.69 | 17.07 | 17.92 | |
| Research And Ddevelopement To Revenue | 0.0208 | 0.0185 | 0.0452 | 0.0595 | 0.0462 | 0.0744 | |
| Capex To Revenue | 0.049 | 0.0655 | 0.13 | 0.0606 | 0.0486 | 0.0462 | |
| Cash Per Share | 1.72 | 2.73 | 4.3 | 3.53 | 3.31 | 3.47 | |
| Pocfratio | 125.75 | 4.0K | (153.17) | (17.39) | (1.0K) | (987.76) | |
| Interest Coverage | 2.26 | (0.3) | (1.97) | (101.66) | (15.6) | (16.38) | |
| Capex To Operating Cash Flow | 0.86 | 19.93 | (2.4) | (0.47) | (14.72) | (13.99) | |
| Pfcf Ratio | 879.86 | (211.53) | (45.05) | (11.85) | (66.13) | (62.83) | |
| Days Payables Outstanding | 33.69 | 35.24 | 22.0 | 23.26 | 21.39 | 20.32 | |
| Income Quality | 2.92 | 0.35 | 3.2 | 0.46 | 0.0222 | 0.0211 | |
| Roe | 0.0158 | 0.006009 | (0.007532) | (0.14) | (0.0934) | (0.0888) | |
| Ev To Operating Cash Flow | 124.04 | 4.0K | (164.24) | (22.66) | (1.2K) | (1.1K) | |
| Pe Ratio | 367.07 | 1.4K | (490.37) | (7.96) | (23.08) | (21.93) | |
| Return On Tangible Assets | 0.0208 | 0.006354 | (0.009271) | (0.18) | (0.11) | (0.12) | |
| Ev To Free Cash Flow | 867.85 | (211.15) | (48.3) | (15.44) | (74.9) | (71.16) | |
| Earnings Yield | 0.002724 | 7.14E-4 | (0.002039) | (0.13) | (0.0433) | (0.0455) | |
| Intangibles To Total Assets | 0.46 | 0.34 | 0.52 | 0.54 | 0.53 | 0.35 | |
| Net Debt To E B I T D A | (0.93) | (0.3) | 5.68 | (4.42) | (15.29) | (14.52) | |
| Current Ratio | 4.55 | 6.13 | 7.81 | 6.73 | 6.2 | 6.51 | |
| Tangible Book Value Per Share | 1.81 | 3.34 | 1.16 | 0.54 | 0.36 | 0.27 | |
| Receivables Turnover | 4.34 | 4.16 | 4.32 | 4.26 | 4.51 | 5.13 | |
| Graham Number | 3.01 | 2.35 | 3.8 | 14.49 | 10.88 | 11.42 |
Pair Trading with NeoGenomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NeoGenomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeoGenomics will appreciate offsetting losses from the drop in the long position's value.Moving together with NeoGenomics Stock
Moving against NeoGenomics Stock
| 0.81 | HCM | HUTCHMED DRC | PairCorr |
| 0.61 | VALN | Valneva SE ADR | PairCorr |
| 0.59 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.55 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.51 | ERNA | Eterna Therapeutics | PairCorr |
The ability to find closely correlated positions to NeoGenomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NeoGenomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NeoGenomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NeoGenomics to buy it.
The correlation of NeoGenomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NeoGenomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NeoGenomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NeoGenomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.306 | Earnings Share (0.60) | Revenue Per Share 5.098 | Quarterly Revenue Growth 0.104 | Return On Assets (0.03) |
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.